Company: MDCXW
Filing Date: 2025-09-19
Form Type: DRS
Source: 0001062993-25-015719
Chunk: 175

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-19
Form: DRS
Chunk 175
---
 |  Salary 
     ($) 
       - | Share-based 
 Awards      
 ($)         
 -           | Option-based 
   Awards ($) 
      100,856 | Pension   
 Value ($) 
 -         |        All Other 
 Compensation ($) 
                - |        Total 
 Compensation 
          ($) 
      100,856 |
|:--------------------|-------------:|--------:|:------------|-------------:|:----------|-----------------:|-------------:|
|                     |         2023 |       - | -           |      132,601 | -         |                - |      132,601 |
| James Quinlan,      
 CFO                 |         2024 | 318,269 | -           |       40,342 | -         |          125,000 |      483,611 |
|                     |         2023 |  93,969 | -           |       66,300 | -         |          100,000 |      260,269 |
| Dr. Edward Brennan, 
 CSO, CMO (2)        |         2024 | 325,710 | -           |       40,342 | -         |          125,000 |      491,052 |
|                     |         2023 |  79,424 | -           |       39,780 | -         |           75,000 |      194,204 |

(1)Dr. Raza Bokhari provided executive services to the Company through an agreement between Medicus and RBx, an entity controlled by Dr. Bokhari. RBx also made available to the Company certain other management services and administrative and executive support. Reimbursable salaries paid to RBx pursuant to this agreement were $125,000 per month through November 2024. In December 2024, reimbursable salaries were changed to $100,000 per month.

(2)Dr. Edward Brennan served as our Chief Medical Officer from September 2023 to November 2024. Dr. Edward Brennan has served as our Chief Scientific Officer & Head of R&D Program since November 2024.

Outstanding Equity Awards at Fiscal Year-End

The following table sets forth certain information concerning equity awards granted to our named executive officers that remained outstanding as of December 31, 2024.

| Name               |    Number of Securities 
  Underlying Unexercised 
 Options Exercisable (#) |   Number of Securities 
 Underlying Un